Jivi 500 Unit

JIVI 500 Unit is a recombinant antihemophilic factor used for hemophilia B treatment. This intravenous powder for solution helps manage bleeding episodes and prevent surgical bleeding.

JIVI 500 Unit is primarily used to control and prevent bleeding in individuals with hemophilia B, a condition characterized by a deficiency in clotting factor IX. This medication is designed to replace the missing clotting factor, thereby aiding in the formation of blood clots. It is often administered intravenously to manage bleeding episodes or to prevent bleeding during surgical procedures. The recombinant nature of JIVI ensures a high level of purity and reduces the risk of transmitting blood-borne infections.

Common effects of JIVI 500 Unit may include localized reactions at the injection site, such as redness, swelling, or discomfort. Some individuals might experience mild flu-like symptoms, including fever, chills, or fatigue. These effects are generally temporary and resolve on their own. Severe allergic reactions are rare but require immediate medical attention.

JIVI 500 Unit should be handled with care, ensuring proper storage and preparation to maintain its efficacy. It is crucial to follow the healthcare provider's instructions for administration and monitoring. Individuals with known allergies to any components of the medication should avoid its use. Regular monitoring of clotting factor levels may be necessary to adjust the dosage as needed.

JIVI 500 Unit may interact with certain medications, particularly those that affect blood clotting. It is important to inform your healthcare provider about all medications, including over-the-counter drugs and supplements, before starting treatment. Alcohol consumption should be moderated, as it can affect the body's ability to clot blood. Always consult a healthcare professional for personalized advice.